News on U.S. government agencies, U.S. politics, companies doing business with U.S. federal government. Read U.S. national and local news. This site is not affiliated with United States Government.
(USGovernment-News.Com, July 13, 2020 ) Diabetes is rising at an alarming rate in the United States. Diabetes referred to as diabetes mellitus, is a group of metabolic diseases in which a person suffers from high blood glucose. If diabetes not appropriately monitored, then it can be fatal and cause serious health complications such as kidney diseases, heart diseases, amputation, stroke and blindness. Between the year 2000 and 2019, the number of people living with diabetes tripled and the number of new cases annually (incidence) doubled in the United States. The United States represents the third-largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels in 2018. United States Diabetes Market is expected to reach USD 23.29 Billion by the year 2025.
The use of continuous glucose monitoring systems and continuous subcutaneous insulin infusion has gained full acceptance in diabetes care. These devices have demonstrated to be clinically valuable, reducing risks of hypoglycemia and improving glycemic control in ambulatory patients with type 1 diabetes & type 2 diabetes. Because of this tremendous improvement in the number of patients, especially that requiring insulin therapy, the cost of healthcare-related to diabetes and its complications is ever increasing. The market of Insulin Pen, Insulin Pump, Continuous Glucose Monitoring (CGM) Device and Self Monitoring Blood Glucose Device are growing due to the rise in numbers of diabetic patients in the United States.
The increasing diabetes prevalence has led the U.S. Government to launch diabetes to raise awareness and prevention programs about its symptoms and encourage healthier lifestyle behavior amongst the citizens. In 2019, Abbott Laboratories planned to ramp up manufacturing capacity for its lower-cost continuous glucose monitor (CGM) device in the next few years, targeting to reach millions of more patients worldwide, According to Reuters. In March 2018, Sanofi-aventis U.S. LLC received approval from the U.S. Food and Drug Administration for Toujeo Max SoloStar.
Renub Research report titled “United States Diabetes Market & Forecast, By Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Self Monitoring Blood Glucose Device Analysis (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Insulin Pen Analysis – (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies), Insulin Pump Market, (Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, USA (By States) – Diabetes Supplies, Insulin Pump & Pump Supplies Reimbursement Policies by State-Sponsored Health Program) Companies (B. Braun Melsungen AG, Eli Lilly and Company, Artsana S.p.A, BD, Novo Nordisk A/S, Owen Mumford Ltd, Ypsomed AG, Medtronic, Insulet Corporation, LifeScan Inc., Abbott Laboratories)" provides a complete analysis of United States Insulin Delivery Devices Market.
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:
